

# RECORD OF TELEPHONE CONVERSATION

## Submission Information

<b>Application Type</b>	BLA
<b>STN</b>	125597/0.0
<b>Review Office</b>	OVRR
<b>Applicant</b>	Pax Vax Bermuda Ltd. / Lic. # 2041
<b>Product</b>	Cholera Vaccine Live Oral
<b>Trans-BLA Group:</b>	No

## Telecon Details

<b>Telecon Date/Time</b>	06-APR-2016 11:45 AM
<b>Author</b>	SEN, GOUTAM
<b>EDR</b>	No
<b>Post to Web</b>	No
<b>Outside Phone Number</b>	
<b>FDA Originated?</b>	Yes
<b>Communication Categories</b>	IR - Information Request
<b>Related STNs</b>	None
<b>Related PMCs</b>	None
<b>Telecon Summary</b>	Requested to submit a concept protocol for pregnancy registry
<b>FDA Participants</b>	Goutam Sen
<b>Applicant Participants</b>	Kevin Smyth

## Telecon Body:

**From:** Sen, Goutam

**Sent:** Wednesday, April 06, 2016 11:35 AM

**To:** Kevin Smyth (KSmyth@paxvax.com)

**Subject:** Information request to submit a concept protocol for pregnancy registry, STN: 125597

## RECORD OF TELEPHONE CONVERSATION

Dear Kevin,

While reviewing your Pharmacovigilance Plan submitted to your original BLA submission, we note that you have proposed a Pregnancy Registry to monitor pregnancy outcomes in women exposed to VAXCHORA during pregnancy. You have also indicated that the Pregnancy Registry will be initiated on licensure and launch of VAXCHORA.

Please submit a Concept Protocol for the proposed Pregnancy Registry to your BLA. You may refer to the FDA Guidance for Establishing Pregnancy Registries at [www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071639.pdf](http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071639.pdf)

Please submit a Concept Protocol to your BLA by April 20, 2016. Also, please provide the projected dates and justification of the proposed dates for the following events pertaining to the pregnancy registry:

Final Protocol Submission  
Study Completion  
Final Report Submission

Please let me know if you have any questions.

**Goutam Sen**, Ph.D.  
Scientific Reviewer  
Food and Drug Administration  
Center for Biologics Evaluation and Research  
White Oak Bldg. 71  
10903 New Hampshire Avenue  
Silver Spring, MD 20993-0002  
Telephone: 301-796-2640  
Fax: 301-595-1125

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.